Omthera Pharmaceuticals develops therapies for patients with elevated triglyceride levels and increased risk of cardiovascular disease.
Business Model:
Revenue: $0
Employees: 11-50
Omthera was acquired by
AstraZeneca.
The acquisition happend on 2013-05-29.
Details of the transaction were not public
Address:
City: Princeton
State: New Jersey
Zip:
Country: United States
Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2011 | Series B | 2 | $33.9M |
New Enterprise Associates Sofinnova Partners New Enterprise Associates Sofinnova Partners |
3/2010 | Series A | 1 | $6.5M |
Sofinnova Partners Sofinnova Partners |
11/2009 | Venture Round | $2.2M | 2/2013 | Debt Financing | $17.6M |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|